Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by TheBearInTheWoodson Jan 27, 2021 11:59am

207 Views

Post# 32399380

Another one bites the dust - Apli

[url=https://www.google.ca/amp/s/www.ndtv.com/business/dr-reddys-completes-review-of-covid-19-drug-avigan-in-kuwait-2358888%3famp=1&akamai-rum=off]https://www.google.ca/amp/s/www.ndtv.com/business/dr-reddys-completes-review-of-covid-19-drug-avigan-in-kuwait-2358888%3famp=1&akamai-rum=off[/url]

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec